Capricor Historical Balance Sheet

CAPR Stock

USD 12.20 0.98 7.44%

Trend analysis of Capricor Therapeutics balance sheet accounts such as Total Current Liabilities of 37.8 M, Total Stockholder Equity of 71.7 M or Accounts Payable of 7.5 M provides information on Capricor Therapeutics' total assets, liabilities, and equity, which is the actual value of Capricor Therapeutics to its prevalent stockholders. By breaking down trends over time using Capricor Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Capricor Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Capricor Therapeutics is a good buy for the upcoming year.

Capricor Therapeutics Inventory

0.86

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Capricor Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Capricor Stock, please use our How to Invest in Capricor Therapeutics guide.

About Capricor Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Capricor Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Capricor Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Capricor Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Capricor currently owns. An asset can also be divided into two categories, current and non-current.

Capricor Therapeutics Balance Sheet Chart

At this time, Capricor Therapeutics' Cash is relatively stable compared to the past year. As of 03/27/2025, Cash And Short Term Investments is likely to grow to about 89.3 M, though Non Current Assets Total are likely to grow to (80.8 M).

Total Assets Total Current Liabilities Accounts Payable Common Stock Total Equity Accumulated Depreciation

Add Fundamental

Total Assets

Total assets refers to the total amount of Capricor Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Capricor Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Capricor Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Capricor Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Capricor Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Capricor Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Accumulated Depreciation

Accumulated depreciation is the total amount of depreciation for Capricor Therapeutics fixed asset that has been charged to Capricor Therapeutics expense since that asset was acquired and made available for Capricor Therapeutics use. The accumulated depreciation account is Capricor Therapeutics asset account with a credit balance. It is also known as a contra asset account and appears on the balance sheet as a reduction from the gross amount of fixed assets reported by Capricor Therapeutics.

Most accounts from Capricor Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Capricor Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Capricor Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Capricor Stock, please use our How to Invest in Capricor Therapeutics guide.At this time, Capricor Therapeutics' Cash is relatively stable compared to the past year. As of 03/27/2025, Cash And Short Term Investments is likely to grow to about 89.3 M, though Non Current Assets Total are likely to grow to (80.8 M).

	2022	2023	2024	2025 (projected)
Total Current Liabilities	23.6M	31.3M	36.0M	37.8M
Total Assets	50.1M	58.7M	67.5M	70.9M

Total Current Liabilities Total Assets

Capricor Therapeutics balance sheet Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Common Stock	Net Debt	Cash	Cash And Short Term Investments	Net Receivables	Total Current Assets	Other Current Liab	Short Long Term Debt Total	Short Term Debt	Property Plant And Equipment Net	Other Current Assets	Property Plant And Equipment Gross	Intangible Assets	Net Tangible Assets	Other Assets
Total Assets		0.92	0.86	-0.92	0.98	-0.63	-0.69	0.11	0.98	0.95	-0.4	0.22	-0.53	0.6	0.95	0.83	0.97	-0.07	-0.14	-0.44	0.96	0.86	0.95	-0.14	0.52	0.92
Total Current Liabilities	0.92		0.78	-0.82	0.95	-0.72	-0.77	0.11	0.89	0.86	-0.47	0.24	-0.17	0.26	0.9	0.92	0.93	-0.38	-0.16	-0.31	0.95	0.67	0.96	-0.14	0.18	0.84
Total Stockholder Equity	0.86	0.78		-0.75	0.83	-0.86	-0.88	0.14	0.9	0.89	-0.78	0.23	-0.52	0.53	0.95	0.84	0.94	0.02	-0.32	-0.47	0.83	0.83	0.84	-0.08	0.54	0.81
Retained Earnings	-0.92	-0.82	-0.75		-0.87	0.46	0.52	-0.31	-0.92	-0.97	0.25	-0.41	0.51	-0.51	-0.83	-0.73	-0.86	-0.07	0.2	0.46	-0.91	-0.85	-0.9	-0.01	-0.59	-0.9
Accounts Payable	0.98	0.95	0.83	-0.87		-0.67	-0.72	0.11	0.94	0.91	-0.42	0.22	-0.4	0.53	0.94	0.86	0.96	-0.17	-0.03	-0.32	0.94	0.77	0.95	-0.14	0.37	0.89
Non Current Assets Total	-0.63	-0.72	-0.86	0.46	-0.67		1.0	-0.09	-0.67	-0.64	0.94	-0.17	0.08	-0.17	-0.83	-0.8	-0.79	0.26	0.16	0.19	-0.65	-0.5	-0.67	0.06	-0.08	-0.57
Non Currrent Assets Other	-0.69	-0.77	-0.88	0.52	-0.72	1.0		-0.09	-0.72	-0.68	0.91	-0.18	0.11	-0.2	-0.86	-0.83	-0.83	0.27	0.17	0.21	-0.71	-0.54	-0.73	0.07	-0.11	-0.63
Common Stock Total Equity	0.11	0.11	0.14	-0.31	0.11	-0.09	-0.09		0.15	0.26	-0.09	0.98	-0.13	0.04	0.11	0.12	0.11	-0.1	-0.02	0.2	0.16	0.04	0.16	0.16	0.15	0.09
Common Stock Shares Outstanding	0.98	0.89	0.9	-0.92	0.94	-0.67	-0.72	0.15		0.97	-0.48	0.25	-0.54	0.56	0.95	0.82	0.96	-0.02	-0.28	-0.47	0.97	0.9	0.97	-0.12	0.58	0.94
Other Stockholder Equity	0.95	0.86	0.89	-0.97	0.91	-0.64	-0.68	0.26	0.97		-0.46	0.36	-0.54	0.55	0.92	0.81	0.94	0.05	-0.26	-0.48	0.94	0.89	0.93	-0.02	0.6	0.92
Total Liab	-0.4	-0.47	-0.78	0.25	-0.42	0.94	0.91	-0.09	-0.48	-0.46		-0.15	0.07	-0.09	-0.65	-0.64	-0.6	0.13	0.28	0.19	-0.43	-0.38	-0.46	0.01	-0.09	-0.38
Common Stock	0.22	0.24	0.23	-0.41	0.22	-0.17	-0.18	0.98	0.25	0.36	-0.15		-0.15	0.07	0.21	0.26	0.22	-0.14	-0.05	0.15	0.27	0.12	0.27	0.14	0.17	0.19
Net Debt	-0.53	-0.17	-0.52	0.51	-0.4	0.08	0.11	-0.13	-0.54	-0.54	0.07	-0.15		-0.93	-0.45	-0.17	-0.45	-0.5	0.18	0.48	-0.36	-0.7	-0.34	0.16	-0.93	-0.45
Cash	0.6	0.26	0.53	-0.51	0.53	-0.17	-0.2	0.04	0.56	0.55	-0.09	0.07	-0.93		0.53	0.23	0.54	0.46	0.12	-0.33	0.39	0.66	0.38	-0.17	0.8	0.48
Cash And Short Term Investments	0.95	0.9	0.95	-0.83	0.94	-0.83	-0.86	0.11	0.95	0.92	-0.65	0.21	-0.45	0.53		0.86	1.0	-0.11	-0.16	-0.4	0.92	0.82	0.92	-0.13	0.44	0.87
Net Receivables	0.83	0.92	0.84	-0.73	0.86	-0.8	-0.83	0.12	0.82	0.81	-0.64	0.26	-0.17	0.23	0.86		0.88	-0.33	-0.22	-0.29	0.86	0.63	0.88	-0.1	0.16	0.75
Total Current Assets	0.97	0.93	0.94	-0.86	0.96	-0.79	-0.83	0.11	0.96	0.94	-0.6	0.22	-0.45	0.54	1.0	0.88		-0.12	-0.15	-0.4	0.94	0.83	0.94	-0.13	0.44	0.89
Other Current Liab	-0.07	-0.38	0.02	-0.07	-0.17	0.26	0.27	-0.1	-0.02	0.05	0.13	-0.14	-0.5	0.46	-0.11	-0.33	-0.12		-0.09	-0.31	-0.18	0.31	-0.2	0.44	0.61	0.08
Short Long Term Debt Total	-0.14	-0.16	-0.32	0.2	-0.03	0.16	0.17	-0.02	-0.28	-0.26	0.28	-0.05	0.18	0.12	-0.16	-0.22	-0.15	-0.09		0.64	-0.25	-0.35	-0.25	-0.12	-0.36	-0.28
Short Term Debt	-0.44	-0.31	-0.47	0.46	-0.32	0.19	0.21	0.2	-0.47	-0.48	0.19	0.15	0.48	-0.33	-0.4	-0.29	-0.4	-0.31	0.64		-0.42	-0.66	-0.4	-0.24	-0.59	-0.55
Property Plant And Equipment Net	0.96	0.95	0.83	-0.91	0.94	-0.65	-0.71	0.16	0.97	0.94	-0.43	0.27	-0.36	0.39	0.92	0.86	0.94	-0.18	-0.25	-0.42		0.81	1.0	-0.11	0.42	0.95
Other Current Assets	0.86	0.67	0.83	-0.85	0.77	-0.5	-0.54	0.04	0.9	0.89	-0.38	0.12	-0.7	0.66	0.82	0.63	0.83	0.31	-0.35	-0.66	0.81		0.8	0.11	0.78	0.89
Property Plant And Equipment Gross	0.95	0.96	0.84	-0.9	0.95	-0.67	-0.73	0.16	0.97	0.93	-0.46	0.27	-0.34	0.38	0.92	0.88	0.94	-0.2	-0.25	-0.4	1.0	0.8		-0.11	0.4	0.94
Intangible Assets	-0.14	-0.14	-0.08	-0.01	-0.14	0.06	0.07	0.16	-0.12	-0.02	0.01	0.14	0.16	-0.17	-0.13	-0.1	-0.13	0.44	-0.12	-0.24	-0.11	0.11	-0.11		-0.03	0.08
Net Tangible Assets	0.52	0.18	0.54	-0.59	0.37	-0.08	-0.11	0.15	0.58	0.6	-0.09	0.17	-0.93	0.8	0.44	0.16	0.44	0.61	-0.36	-0.59	0.42	0.78	0.4	-0.03		0.55
Other Assets	0.92	0.84	0.81	-0.9	0.89	-0.57	-0.63	0.09	0.94	0.92	-0.38	0.19	-0.45	0.48	0.87	0.75	0.89	0.08	-0.28	-0.55	0.95	0.89	0.94	0.08	0.55

Click cells to compare fundamentals

Capricor Therapeutics Account Relationship Matchups

Capricor Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	34.6M	41.3M	50.1M	58.7M	67.5M	70.9M
Total Current Liabilities	3.0M	4.1M	23.6M	31.3M	36.0M	37.8M
Total Stockholder Equity	28.2M	31.4M	11.8M	22.6M	68.3M	71.7M
Retained Earnings	(88.0M)	(108.1M)	(137.1M)	(159.4M)	(143.4M)	(136.3M)
Accounts Payable	2.7M	3.7M	4.8M	6.2M	7.2M	7.5M
Non Current Assets Total	941.7K	4.9M	7.2M	7.9M	(85.0M)	(80.8M)
Non Currrent Assets Other	779.0K	88.7K	275.7K	268.2K	(85.0M)	(80.8M)
Common Stock Total Equity	5.2K	20.6K	24.2K	25.2K	29.0K	20.1K
Common Stock Shares Outstanding	15.6M	23.1M	24.6M	26.8M	35.2M	37.0M
Liabilities And Stockholders Equity	34.6M	41.3M	50.1M	58.7M	67.5M	70.9M
Other Stockholder Equity	116.2M	139.4M	148.7M	181.7M	209.0M	219.4M
Total Liab	6.4M	10.0M	38.3M	36.1M	(68.3M)	(64.9M)
Common Stock	20.6K	24.2K	25.2K	31.1K	35.8K	20.7K
Net Debt	(32.3M)	(32.0M)	(7.0M)	(12.5M)	(11.2M)	(10.7M)
Cash	32.7M	34.9M	9.6M	14.7M	16.9M	17.7M
Cash And Short Term Investments	32.7M	34.9M	41.4M	39.5M	85.0M	89.3M
Net Receivables	56K	391.8K	547.6K	10.4M	11.9M	12.5M
Total Current Assets	33.7M	36.4M	42.9M	50.9M	85.0M	89.3M
Short Long Term Debt Total	3.7M	3.8M	4.1M	2.2M	2.6M	2.4M
Property Plant And Equipment Net	850.8K	4.6M	6.9M	7.6M	8.8M	9.2M
Other Current Assets	1.0M	1.2M	919.9K	995.8K	1.1M	1.2M
Property Plant And Equipment Gross	850.8K	5.4M	8.1M	9.8M	11.3M	11.9M
Net Tangible Assets	6.8M	28.2M	36.7M	11.8M	13.6M	7.6M
Other Assets	119.6K	88.7K	275.7K	268.2K	308.4K	323.8K
Retained Earnings Total Equity	(74.4M)	(88.0M)	(108.1M)	(137.1M)	(123.4M)	(117.2M)
Capital Surpluse	81.2M	116.2M	139.4M	148.7M	171.0M	179.6M
Inventory	285.8K	(659.4K)	(56K)	1.0	0.9	0.86
Property Plant Equipment	442.8K	850.8K	4.6M	4.6M	5.3M	5.5M
Non Current Liabilities Total	3.4M	5.8M	14.7M	4.9M	(68.3M)	(64.9M)

Pair Trading with Capricor Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Capricor Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Capricor Therapeutics will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Capricor Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Capricor Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Capricor Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Capricor Therapeutics to buy it.

The correlation of Capricor Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Capricor Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Capricor Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Capricor Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Capricor Stock Analysis

When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Capricor Historical Balance Sheet

Capricor Therapeutics Inventory

0.86

About Capricor Balance Sheet Analysis

Capricor Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Common Stock Total Equity

Accumulated Depreciation

Capricor Therapeutics balance sheet Correlations

Capricor Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Capricor Therapeutics balance sheet Accounts

Pair Trading with Capricor Therapeutics

Additional Tools for Capricor Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Currrent Assets Other	+ 1.0	Non Current Assets Total
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Accounts Payable	+ 0.98	Total Assets
Common Stock Shares Outstanding	+ 0.98	Total Assets
Common Stock	+ 0.98	Common Stock Total Equity

Other Stockholder Equity	- 0.97	Retained Earnings
Net Tangible Assets	- 0.93	Net Debt
Cash	- 0.93	Net Debt
Common Stock Shares Outstanding	- 0.92	Retained Earnings
Retained Earnings	- 0.92	Total Assets
Property Plant And Equipment Net	- 0.91	Retained Earnings